Oral administration of circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses.
Although cognitive performance in humans and experimental animals can be improved by administering omega-3 fatty acid docosahexaenoic acid (DHA), the neurochemical mechanisms underlying this effect remain uncertain. In general, nutrients or drugs that modify brain function or behavior do so by affecting synaptic transmission, usually by changing the quantities of particular neurotransmitters present within synaptic clefts or by acting directly on neurotransmitter receptors or signal-transduction molecules. We find that DHA also affects synaptic transmission in mammalian brain. Brain cells of gerbils or rats receiving this fatty acid manifest increased levels of phosphatides and of specific presynaptic or postsynaptic proteins. They also exhibit increased numbers of dendritic spines on postsynaptic neurons. These actions are markedly enhanced in animals that have also received the other two circulating precursors for phosphatidylcholine, uridine (which gives rise to brain uridine diphosphate and cytidine triphosphate) and choline (which gives rise to phosphocholine). The actions of DHA aere reproduced by eicosapentaenoic acid, another omega-3 compound, but not by omega-6 fatty acid arachidonic acid. Administration of circulating phosphatide precursors can also increase neurotransmitter release (acetylcholine, dopamine) and affect animal behavior. Conceivably, this treatment might have use in patients with the synaptic loss that characterizes Alzheimer's disease or other neurodegenerative diseases or occurs after stroke or brain injury.
Cansev
Mehmet
M
Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.
Wurtman
Richard J
RJ
Sakamoto
Toshimasa
T
Ulus
Ismail H
IH
D000284:Administration, Oral; D000818:Animals; D001921:Brain / Q000187:drug effects*; D001927:Brain Diseases / Q000628:therapy; D002462:Cell Membrane / Q000737:chemistry*; D002794:Choline / Q000008:administration & dosage; D004281:Docosahexaenoic Acids / Q000008:administration & dosage; D006801:Humans; D008563:Membrane Lipids / Q000008:administration & dosage / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism*; D011355:Prodrugs / Q000008:administration & dosage*; D013569:Synapses / Q000187:drug effects*; D009435:Synaptic Transmission / Q000187:drug effects; D014529:Uridine / Q000008:administration & dosage
D008563:Membrane Lipids; D010743:Phospholipids; D011355:Prodrugs; D004281:Docosahexaenoic Acids; D002794:Choline; D014529:Uridine